Back to top
more

INC Research Holdings, Inc. (SYNH)

(Delayed Data from NSDQ)

$47.27 USD

47.27
483,054

+0.56 (1.20%)

Updated May 3, 2019 04:00 PM ET

After-Market: $47.36 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Implied Volatility Surging for Syneos Health (SYNH) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Syneos Health (SYNH) stock based on the movements in the options market lately.

Syneos Health (SYNH) to Launch Serplulimab With New Pact

by Zacks Equity Research

Syneos Health's (SYNH) new partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today's changing environment.

Syneos Health (SYNH) Hurt by Low Reimbursable Expense, FX Issue

by Zacks Equity Research

Syneos Health (SYNH) experiences delays in large pharma award decisions, with net awards being impacted by greater-than-normal delays.

Syneos Health (SYNH) to Enhance Clinical Trials With New Pact

by Zacks Equity Research

Syneos Health's (SYNH) extended partnership is part of the company's commitment to bringing clinical trials closer to the patient.

Syneos Health (SYNH) Q3 Earnings Miss Estimates, '22 View Cut

by Zacks Equity Research

Syneos Health (SYNH) Q3 revenues are below the guidance primarily due to the impact of lower net new business awards, delays in backlog conversion and customer delays in its FSP business.

1Life Healthcare, Inc. (ONEM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

1Life Healthcare, Inc. (ONEM) delivered earnings and revenue surprises of -21.28% and 3.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

IRhythm Technologies (IRTC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 23.17% and 2.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Inspire (INSP) Soars 7.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Inspire (INSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here's Why Investors Should Retain Syneos Health (SYNH) for Now

by Zacks Equity Research

Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental results.

Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View

by Zacks Equity Research

Syneos Health (SYNH) posts better-than-expected earnings in the second quarter and robust results across the Clinical Solutions and Commercial Solutions businesses.

Syneos Health (SYNH) Beats Q2 Earnings Estimates

by Zacks Equity Research

Syneos Health (SYNH) delivered earnings and revenue surprises of 4.17% and 1.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AllScripts Healthcare (MDRX) Q2 Earnings Expected to Decline

by Zacks Equity Research

AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syneos Health (SYNH) is a Top-Ranked Growth Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Investors Should Retain Syneos Health (SYNH) For Now

by Zacks Equity Research

Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.

Syneos Health (SYNH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Syneos Health (SYNH) delivered earnings and revenue surprises of 5.21% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CareCloud, Inc. (MTBC) Stock Jumps 15.5%: Will It Continue to Soar?

by Zacks Equity Research

CareCloud, Inc. (MTBC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Should Value Investors Pick Syneos Health (SYNH) Stock Now?

by Zacks Equity Research

Let's see if Syneos Health, Inc. (SYNH) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe

by Zacks Equity Research

Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.

Medtronic (MDT) Boosts Surgical Robotics Wing With New Deal

by Zacks Equity Research

According to Medtronic (MDT), Touch Surgery Enterprise is the first AI-powered platform of its kind for the operating room (OR). It is compatible with Medtronic's Hugo robotic-assisted surgery (RAS) system.

Here's Why You Should Retain Syneos Health (SYNH) For Now

by Zacks Equity Research

Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental performance.

Riya Anand headshot

4 Stocks in Spotlight With AI Making Inroads in MedTech

by Riya Anand

MedTech stocks like Medtronic (MDT), Stryker (SYK), Allscripts Healthcare Solutions (MDRX) and Syneos Health (SYNH) are evolving rapidly in the field of AI-driven technologies.